COMPANY
Exavir Therapeutics
Funding and NIH signals
- NIH award NIH awarded $998K (SBIR Phase II 1R44AI195119-01, new, notice Aug 4, 2026). NIH RePORTER 1R44AI195119-01 (Aug 4, 2026)
Evidence (1 event)
- Aug 4, 2026 · NIH RePORTER 1R44AI195119-01
Organization: EXAVIR THERAPEUTICS INC.; City/State: San Francisco, CA; Project number: 1R44AI195119-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 998034; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infection; Organization type: Domestic For-Profits
- Aug 4, 2026 · NIH RePORTER 1R44AI195119-01